I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue surged 127% year-over-year to $1.3 million, with gross margin rising to 64%. Net loss widened to $4.1 million due to higher operating expenses and non-cash interest, while a $4.2 million public offering and FDA clearance for a key product support future growth.Original document: Tenon Medical, Inc. [TNON] SEC 8-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue surged 127% year-over-year to $1.3 million, with gross margin rising to 64%. Net loss widened to $4.1 million due to higher operating expenses and non-cash interest, while a $4.2 million public offering and FDA clearance for a key product support future growth.
Original document: Tenon Medical, Inc. [TNON] SEC 8-K Current Report — Aug. 13 2026